Saeed Lina, Hosking Anna-Marie, Grando Sergei A
Department of Dermatology, University of California Irvine, Irvine, CA, USA.
Skin Health Dis. 2025 Jan 29;5(1):53-55. doi: 10.1093/skinhd/vzae008. eCollection 2025 Feb.
Programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) receptor inhibitors have become imperative in the treatment of advanced solid organ malignancies such as metastatic melanoma. With this disinhibition of certain immune responses to induce an antitumour response, numerous adverse events have been reported, many of which affect the skin. While rare, PD-1/PD-L1 inhibitor-associated severe cutaneous adverse reactions (SCARs) can cause significant morbidity and/or mortality. New SCARs are reported with increasing frequency as immune checkpoint inhibitors become more widely used. Here, we present a rare case of recalcitrant ocular linear IgA bullous dermatosis associated with a PD-1 inhibitor. Awareness of this entity will allow more rapid recognition and initiation of appropriate management and treatment, which would reduce the morbidity and/or mortality associated with these serious adverse reactions.
程序性死亡受体1（PD-1）和程序性死亡配体1（PD-L1）受体抑制剂已成为治疗晚期实体器官恶性肿瘤（如转移性黑色素瘤）的关键药物。随着某些免疫反应的去抑制以诱导抗肿瘤反应，已报告了许多不良事件，其中许多影响皮肤。虽然罕见，但PD-1/PD-L1抑制剂相关的严重皮肤不良反应（SCARs）可导致显著的发病率和/或死亡率。随着免疫检查点抑制剂的使用越来越广泛，新的SCARs报告频率也在增加。在此，我们报告一例与PD-1抑制剂相关的顽固性眼部线状IgA大疱性皮肤病罕见病例。认识到这一实体将有助于更快速地识别并启动适当的管理和治疗，从而降低与这些严重不良反应相关的发病率和/或死亡率。
